Page last updated: 2024-10-31

metyrapone and Carcinoma, Small Cell

metyrapone has been researched along with Carcinoma, Small Cell in 1 studies

Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.
metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.

Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dimopoulos, MA1
Fernandez, JF1
Samaan, NA1
Holoye, PY1
Vassilopoulou-Sellin, R1

Other Studies

1 other study available for metyrapone and Carcinoma, Small Cell

ArticleYear
Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer.
    Cancer, 1992, Jan-01, Volume: 69, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Cushing Syndrome; Female; Humans; Lung Ne

1992